Immunocore Holdings plc (ADR)
General ticker "IMCR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.6B (TTM average)
Immunocore Holdings plc (ADR) follows the US Stock Market performance with the rate: 48.7%.
Estimated limits based on current volatility of 3.4%: low 36.53$, high 39.13$
Factors to consider:
- Total employees count: 493 (-0.8%) as of 2024
- US accounted for 91.5% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Operational and conduct risks, Regulatory and compliance, Market disruptions, Cybersecurity threats, Labor/talent shortage/retention
- Current price 13.7% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [15.10$, 35.38$]
- 2025-12-31 to 2026-12-31 estimated range: [13.48$, 31.42$]
Financial Metrics affecting the IMCR estimates:
- Negative: with PPE of -28.3 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: 18.93 < Shareholder equity ratio, % of 35.73 <= 41.86
- Positive: Inventory ratio change, % of 0.38 <= 0.84
- Negative: Operating cash flow per share per price, % of 1.81 <= 6.82
Short-term IMCR quotes
Long-term IMCR plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | £144.23MM | £249.43MM | £247.77MM |
| Operating Expenses | £187.01MM | £309.08MM | £304.05MM |
| Operating Income | £-42.77MM | £-59.65MM | £-56.28MM |
| Non-Operating Income | £8.95MM | £-1.24MM | £14.00MM |
| Interest Expense | £5.41MM | £5.15MM | £18.84MM |
| R&D Expense | £84.31MM | £163.54MM | £177.44MM |
| Income(Loss) | £-33.82MM | £-60.89MM | £-42.28MM |
| Taxes | £9.65MM | £-5.60MM | £-1.48MM |
| Profit(Loss)* | £-34.39MM | £-67.21MM | £-51.09MM |
| Stockholders Equity | £338.90MM | £368.84MM | £360.72MM |
| Inventory | £0.69MM | £4.50MM | £5.45MM |
| Assets | £526.76MM | £597.00MM | £1,009.51MM |
| Operating Cash Flow | £-49.21MM | £2.94MM | £26.06MM |
| Capital expenditure | £2.20MM | £5.42MM | £5.17MM |
| Investing Cash Flow | £-2.20MM | £-5.42MM | £-355.13MM |
| Financing Cash Flow | £145.44MM | £34.35MM | £343.88MM |
| Earnings Per Share** | £-0.75 | £-1.37 | £-1.02 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.